2018 年第 7 期 第 13 卷

乳腺癌免疫治疗中程序性细胞死亡受体1及其配体通路作用的相关研究进展

Research progress of programmed cell death receptor-1 and its ligand in immunotherapy of breast cancer

作者：赵丹王伏生路晓庆姚天婍王静之

英文作者：

单位：030001太原，山西医科大学第二医院乳腺外科

英文单位：

关键词：乳腺肿瘤；免疫治疗；程序性细胞死亡受体1

英文关键词：

• 摘要：

• 【摘要】免疫逃逸在肿瘤的发生发展中发挥了重要作用，程序性细胞死亡受体1（PD-1）是在免疫反应中T细胞表面表达的免疫检查点抑制剂，主要由其配体PD-L1激活，PD-1/PD-L1信号通路主要通过降低T淋巴细胞活化、抑制T淋巴细胞增殖和诱导特异性T细胞凋亡而发挥负性调节的作用。在多种肿瘤细胞包括乳腺癌（尤其是具有高增殖指数的乳腺癌亚型）中，PD-1/PD-L1的表达都会上调，说明PD-1/PD-L1信号通路可能是主要的免疫逃逸机制之一。已有多项研究表明特异性抗体阻断PD-1或PD-L1对乳腺癌有一定疗效。

  
  

• 【Abstract】Immune escape plays an important role in occurrence and development of cancer, programmed cell death receptor-1(PD-1) is an immune checkpoint inhibitor expressed on T cells. PD-1 and its ligand PD-L1 may have negative regulatory effects by decreasing activation, inhibiting proliferation and inducing apoptosis on T cells. PD-1/PD-L1 pathway is considered to be a major mechanism of immune escape; it shows high expression in many tumors including breast tumor, especially in highly proliferative breast cancer. Anti-PD-1/PD-L1 specific antibodies have been proved to have certain curative effect on breast cancer.

  【Key words】Breast neoplasms;Immunotherapy;Programmed cell death receptor-1

  【Fund program】General Social Development Program of Key Research and Development Project of Shanxi Province（2010703D321014-1）